HomepageMedicineFDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes Medicine FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes admin Posted on February 18, 2025 Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostArvind SmartSpaces sign ₹600-cr real estate deal in Ahmedabad Next PostXi Jinping's educational philosophy now in four new languages You Might Also Like Medicine Recent Licensing Agreement Poised to Advance Company ADC admin January 28, 2024 Medicine Building Resiliency: Essential Leadership Principles for 2024 admin February 14, 2024 Medicine Overall Impact of AI-Driven Discovery Platforms admin February 6, 2025 Medicine FDA Approves Incyte and Syndax Pharmaceuticals’ Niktimvo for Treating Chronic Graft-Versus-Host Disease admin August 20, 2024
Medicine FDA Approves Incyte and Syndax Pharmaceuticals’ Niktimvo for Treating Chronic Graft-Versus-Host Disease admin August 20, 2024